Research professionals are encouraged to use the contact information on the "Our Team" page of this site to get in touch with members of the NCPC team, or email us at ncpc@northwestern.edu for more information about chemoprevention trials.
Information regarding previous publications and findings can be found in the "Completed Trials" section of our website.
Have you been diagnosed with Lynch Syndrome (LS)?
Lynch Syndrome (LS) increases the risk of colon cancer and can also increase the risk of other cancers, including cancer of the uterus, ovaries, small bowel, stomach, pancreas, urinary tract, skin and brain. Cancer prevention strategies for people with LS are therefore urgently needed. Using vaccines to train the body’s own immune system to prevent polyps and cancers is a new approach that we plan to test in patients with LS.
Testing a combination of vaccines for cancer prevention in Lynch Syndrome
Principal Investigators: Ajay Bansal, MD - University of Kansas Medical Center
Eduardo Vilar-Sanchez, MD, PhD, University of Texas MD Anderson Cancer Center
The purpose of this study is to compare the safety and effects of the Tri-Ad5 vaccines alone, or in combination with N-803, versus placebo on the risk of developing colon and other cancers in patients with Lynch syndrome. The Tri-Ad5 vaccines and N-803 are not FDA-approved. This study will soon be looking for volunteers who have been diagnosed with Lynch syndrome. We will enroll 158 participants at institutions across the country.
You may be eligible if:
-
You have been diagnosed with Lynch syndrome and have had abnormal growths in your colon or rectum
-
You have not had any cancer treatment in the past 6 months
-
You are 18 years or older
-
You are not pregnant or planning to get pregnant
If you think you may be eligible, you can contact ncpc@northwestern.edu to refer you to the study team closest to you.
Site: University of Kansas Medical Center, Kansas City, KS
Protocol and Site Principal Investigator: Ajay Bansal, MD
Site: University of Texas MD Anderson Cancer Center, Houston, TX
Protocol and Site Principal Investigator: Eduardo Vilar-Sanchez, MD, PhD
Site: Northwestern University, Chicago, IL
Investigator: Mohammad Abbass, MD
Site: Cleveland Clinic, Cleveland, OH
Investigator: Carol Burke, MD
Site: University of Puerto Rico, San Juan, Puerto Rico
Investigator: Marcia R. Cruz-Correa, M.D., Ph.D., AGAF, FASGE
Site: Ohio State University, Columbus, OH
Investigator: Peter Stanich, MD
Site: University of Utah, Salt Lake City, UT
Investigator: Joanne Jeter, MD, MS
Site: Mayo Clinic Rochester, Rochester, MN
Investigator: Lisa Boardman, MD
Site: Dana-Farber Cancer Institute, Boston, MA
Investigator: Ramona Lim, MD
Site: University of Colorado, Aurora, CO
Investigator: Swati G. Patel, MD, MS
Site: Mayo Clinic at Arizona, Phoenix, AZ
Investigator: Niloy Jewel Samadder, MD, MSc, FRCPC
Site: University of Arizona Cancer Center, Tucson, AZ
Investigator: Aaron James Scott, MD
Site: University of Michigan, Ann Arbor, MI
Investigator: Elena Stoffel, MD, MPH
Site: University of California San Francisco Medical Center
Investigator: Aparajita Singh, MD, MPH
More Information: https://clinicaltrials.gov/ct2/show/NCT05419011
Additional Resources
Study Brochure
